C07K 2317/528
Ch4 domain
Official title: CH4 domain
C07K2317/528 (Ch4 domain) appears on 73 US grants and 125 published applications in this corpus.
Search patents in C07K- Granted patents
- 73
- Published applications
- 125
- Assignees
- 58
- Inventors
- 213
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 4 |
| 2013 | 0 | 2 |
| 2014 | 3 | 8 |
| 2015 | 3 | 4 |
| 2016 | 5 | 7 |
| 2017 | 3 | 7 |
| 2018 | 4 | 12 |
| 2019 | 4 | 10 |
| 2020 | 5 | 13 |
| 2021 | 14 | 12 |
| 2022 | 4 | 10 |
| 2023 | 9 | 10 |
| 2024 | 6 | 7 |
| 2025 | 9 | 10 |
| 2026 | 3 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Antibody constant region variant11 Aug 2026US 12,703,738 B2Chugai Seiyaku Kabushiki Kaisha
- IgM Fc and j-chain mutations that affect IgM serum half-life9 Jun 2026US 12,649,791 B2IGM Biosciences, Inc.
- Agonistic CD40 antibodies3 Mar 2026US 12,565,533 B2Mab Discovery GmbH
- Protein complex by use of a specific site of an immunoglobulin fragment for linkage30 Dec 2025US 12,508,298 B2Hanmi Pharm. Co., Ltd.
- PD1 and VEGFR2 dual-binding agents25 Nov 2025US 12,479,920 B2Ottimo Pharma Limited
- Pd1 and vegfr2 dual-binding agents18 Jun 2026US 2026/0167726 A1Ottimo Pharma Limited
- Protein complex by use of a specific site of an immunoglobulin fragment for linkage11 Jun 2026US 2026/0158112 A1Hanmi Pharm. Co., Ltd.
- Novel heterodimeric proteins11 Jun 2026US 2026/0159611 A1Xencor, Inc.
- Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides23 Apr 2026US 2026/0109774 A1Juno Therapeutics, Inc.
- Targeting epha3 and uses thereof26 Feb 2026US 2026/0055195 A1The Council of the Queensland Institute of Medical Research
Most cited
By later US patents
- Heterodimeric antibodies to CD3 X CD12370US 9,856,327 B2Xencor, Inc. · 2018
- Immunoglobulin constant region FC receptor binding agents38US 8,680,237 B2Gliknik Inc. · 2014
- Antibody constant region variant30US 10,253,091 B2Chugai Seiyaku Kabushiki Kaisha · 2019
- Heterodimeric proteins25US 9,650,446 B2Xencor, Inc. · 2017
- Long-acting insulin or insulin analogue conjugate19US 10,894,089 B2Hanmi Pharm. Co., Ltd. · 2021